Skip to main content

Table 1 Summary of baseline characteristics (Chinese ITT population)

From: Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

 PazopanibSunitinibTotalP value
Number of patients109100209 
Age, (years)0.8991
 Mean (SD)55.5 (11.57)55.7 (11.16)55.6 (11.35)
 Median (min, max)58 (18, 76)57 (23, 79)57 (18, 79)
Sex, n (%)0.5611
 Female30 (28)24 (24)54 (26)
 Male79 (72)76 (76)155 (74)
Weight (kg), n (%)0.7388
 Mean (SD)66.44 (12.665)67.02 (12.414)66.72 (12.519)
 Median (min, max)67 (36, 110)66 (40, 95)67 (36, 110)
Primary tumor type, n (%)NA
 Renal cell109 (100)100 (100)209 (100)
Histology, n (%)0.4290
 Clear cell107 (98)96 (96)203 (97)
 Predominantly clear cell2 (2)4 (4)6 (3)
Stage at screening, n (%)0.9151
 I1 (< 1)01 (< 1)
 II01 (1)1 (< 1)
 III3 (3)3 (3)6 (3)
 IV104 (95)96 (96)200 (96)
 Missing1 (< 1)01 (< 1)
Metastatic disease at screening, n (%)0.3023
 Yes106 (97)97 (97)203 (97)
 No2 (2)3 (3)5 (2)
 Missing1 (< 1)01 (< 1)
MSKCC risk category, n (%)0.1588
 Favorable risk26 (24)34 (34)60 (29)
 Intermediate risk75 (69)64 (64)139 (67)
 Poor risk6 (6)2 (2)8 (4)
 Unknown2 (2)02 (<1)
Heng risk category, n (%)0.2168
 Favorable risk24 (22)33 (33)57 (27)
 Intermediate risk70 (64)55 (55)125 (60)
 Poor risk14 (13)12 (12)26 (12)
 Unknown1 (< 1)01 (< 1)
  1. ITT Intent to treat, MSKCC Memorial Sloan-Kettering Cancer Center, SD Standard deviation